Reviewing Qualigen Therapeutics (AIXC) & Its Rivals

Qualigen Therapeutics (NASDAQ:AIXC) is one of 458 public companies in the “Pharmaceutical Preparations” industry, but how does it weigh in compared to its rivals? We will compare Qualigen Therapeutics to related companies based on the strength of its dividends, earnings, profitability, risk, institutional ownership, analyst recommendations and valuation.

Insider and Institutional Ownership

3.2% of Qualigen Therapeutics shares are held by institutional investors. Comparatively, 39.1% of shares of all “Pharmaceutical Preparations” companies are held by institutional investors. 1.2% of Qualigen Therapeutics shares are held by insiders. Comparatively, 13.9% of shares of all “Pharmaceutical Preparations” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings for Qualigen Therapeutics and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qualigen Therapeutics	1	0	0	0	1.00
Qualigen Therapeutics Competitors	4898	9969	15994	377	2.38

As a group, “Pharmaceutical Preparations” companies have a potential upside of 65.25%. Given Qualigen Therapeutics’ rivals stronger consensus rating and higher possible upside, analysts plainly believe Qualigen Therapeutics has less favorable growth aspects than its rivals.

Valuation and Earnings

This table compares Qualigen Therapeutics and its rivals revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Qualigen Therapeutics	N/A	-$6.26 million	-0.15
Qualigen Therapeutics Competitors	$432.12 million	-$67.78 million	-10.61

Qualigen Therapeutics’ rivals have higher revenue, but lower earnings than Qualigen Therapeutics. Qualigen Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Volatility & Risk

Qualigen Therapeutics has a beta of 0.39, indicating that its stock price is 61% less volatile than the S&P 500. Comparatively, Qualigen Therapeutics’ rivals have a beta of 5.62, indicating that their average stock price is 462% more volatile than the S&P 500.

Profitability

This table compares Qualigen Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Qualigen Therapeutics	N/A	N/A	-52.57%
Qualigen Therapeutics Competitors	-2,662.14%	-363.93%	-42.95%

Summary

Qualigen Therapeutics rivals beat Qualigen Therapeutics on 9 of the 13 factors compared.

About Qualigen Therapeutics

Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient’s blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.